The news comes during a strong market day, with the S&P 500 gaining 0.3% and the healthcare sector, where Kymera operates, up 2.2%.KYMR Stock Jumps On KT-621 Phase 2b BROADEN2 MilestoneKymera has completed enrollment in the BROADEN2 trial nearly six months ahead of schedule, allowing for an accelerated topline data readout expected by year-end 2026.The company plans to initiate Phase 3 trials for KT-621 by mid-2027, reflecting strong interest in this innovative treatment.“With enrollment now complete, we ar ...